Transaction Information
Phosphorex Inc. announced a majority acquisition by Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector.
Phosphorex is a CDMO specializing in long-acting formulations, nanomedicine, and nucleic acid delivery solutions for leading pharmaceutical and biotechnology companies around the world. The company's formulation development and analytical laboratories offer a range of customized production services, supporting assets from proof of concept through clinical studies.
Ampersand's investment will be used to build out the company's 30,000 square foot facility and establish cGMP manufacturing capabilities to further serve customers. The expansion will include the construction of multiple cGMP production suites, processing and packaging capabilities, and comprehensive process development and analytical testing services.
Ladenburg Thalmann & Co. Inc. acted as Exclusive Financial Advisor to Phosphorex.
About Phosphorex Inc.
Phosphorex is a leading provider of drug delivery technologies and solutions. By harnessing the potential of microspheres and nanoparticles for drug delivery, Phosphorex offers tailored solutions and enabling technologies to optimize a drug's release rate, targeting ability, bioavailability, and deliverability, with the goal of achieving desired therapeutic effects while reducing adverse clinical outcomes. For more information, please visit www.phosphorex.com. About Ampersand Capital Partners Ampersand is a middle market private equity firm with more than $3 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. For more information, please visit www.ampersandcapital.com.
The information and material presented is provided for informational purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or buy any securities mentioned herein.